APA (7th ed.) Citation

R, F., V, B., E, W., C, S., V, L., R, R., . . . M, G. (2020). A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers. Cancer biology & therapy, 21(6), 549. https://doi.org/10.1080/15384047.2020.1737490

Chicago Style (17th ed.) Citation

R, Fujita, et al. "A Novel Non-agonist C-Met Antibody Drug Conjugate with Superior Potency over a C-Met Tyrosine Kinase Inhibitor in C-Met Amplified and Non-amplified Cancers." Cancer Biology & Therapy 21, no. 6 (2020): 549. https://doi.org/10.1080/15384047.2020.1737490.

MLA (9th ed.) Citation

R, Fujita, et al. "A Novel Non-agonist C-Met Antibody Drug Conjugate with Superior Potency over a C-Met Tyrosine Kinase Inhibitor in C-Met Amplified and Non-amplified Cancers." Cancer Biology & Therapy, vol. 21, no. 6, 2020, p. 549, https://doi.org/10.1080/15384047.2020.1737490.